MagArray Inc.

MagArray logo

MagArray, Inc.

521 Cottonwood Drive, Suite 121

Milpitas, CA 95035

Company Overview

There are only three basic steps for protein detection using the MagArray protein chip: First, probes on the surface specifically bind to proteins in the sample. Second, nanotag-labeled antibodies bind to the "captured" proteins, forming so called "sandwich" structures. Finally, an external magnetic field is applied to the chip and the stray magnetic field produced by the nanotags is measured electrically to determine the presence of the target molecule in the sample. Alternatively, DNA fragments can be detected by a conceptually identical procedure: only the character of the probe and detection molecules need be changed.

We have demonstrated our ability to detect proteins such as carcinoembronic antigen (CEA) and troponin (Tn) to the 1 pg/mL concentrations and below. We have also demonstrated the capability of our multiplex assay to detect 4-20 biomarkers, and a linear dynamic range of 6 logs.

There is an evolving revolution in diagnostic medicine being driven by the availability of molecular diagnostic assays. This revolution will accelerate as biomarker panels are established for more and more diseases. Perhaps the most active area in cancer research is the search for biomarker panels specific to the different species of cancer. When such panels are identified the need for a high-sensitivity multiplexed assay will also explode. Such diagnostic assays will be necessary in the research stage as platforms for the establishment of the clinical efficacy for the biomarker panels, but will explode only when the biomarker panels reach the clinical application stage. No presently available molecular diagnostic assay meets the need of the multiplex marker panel application. The unique and remarkable capabilities of the MagArray assay system make it a prime candidate to facilitate and underpin the revolution in diagnostic technology presently emerging in diagnostic medicine.